RU2639876C2 - Мультизамещенные ароматические соединения в качестве ингибиторов тромбина - Google Patents

Мультизамещенные ароматические соединения в качестве ингибиторов тромбина Download PDF

Info

Publication number
RU2639876C2
RU2639876C2 RU2012146194A RU2012146194A RU2639876C2 RU 2639876 C2 RU2639876 C2 RU 2639876C2 RU 2012146194 A RU2012146194 A RU 2012146194A RU 2012146194 A RU2012146194 A RU 2012146194A RU 2639876 C2 RU2639876 C2 RU 2639876C2
Authority
RU
Russia
Prior art keywords
pyridin
amine
triazol
carbonyl
unsubstituted
Prior art date
Application number
RU2012146194A
Other languages
English (en)
Russian (ru)
Other versions
RU2012146194A (ru
Inventor
Кевин Майкл ШОРТ
Сон Минх ФАМ
Дэвид Чарльз УИЛЛЬЯМС
Сомалее ДАТТА
Original Assignee
Версеон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Версеон Корпорейшн filed Critical Версеон Корпорейшн
Publication of RU2012146194A publication Critical patent/RU2012146194A/ru
Application granted granted Critical
Publication of RU2639876C2 publication Critical patent/RU2639876C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012146194A 2010-03-30 2011-03-30 Мультизамещенные ароматические соединения в качестве ингибиторов тромбина RU2639876C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31917510P 2010-03-30 2010-03-30
US61/319,175 2010-03-30
PCT/US2011/030585 WO2011126903A2 (en) 2010-03-30 2011-03-30 Multisubstituted aromatic compounds as inhibitors of thrombin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017144535A Division RU2017144535A (ru) 2010-03-30 2011-03-30 Мультизамещенные ароматические соединения в качестве ингибиторов тромбина

Publications (2)

Publication Number Publication Date
RU2012146194A RU2012146194A (ru) 2014-05-10
RU2639876C2 true RU2639876C2 (ru) 2017-12-25

Family

ID=44763506

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012146194A RU2639876C2 (ru) 2010-03-30 2011-03-30 Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
RU2017144535A RU2017144535A (ru) 2010-03-30 2011-03-30 Мультизамещенные ароматические соединения в качестве ингибиторов тромбина

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017144535A RU2017144535A (ru) 2010-03-30 2011-03-30 Мультизамещенные ароматические соединения в качестве ингибиторов тромбина

Country Status (15)

Country Link
US (5) US9533967B2 (enExample)
EP (1) EP2560966B1 (enExample)
JP (3) JP6155187B2 (enExample)
KR (3) KR102113960B1 (enExample)
CN (3) CN110269856A (enExample)
AU (3) AU2011238616B2 (enExample)
BR (1) BR112012024678A2 (enExample)
CA (1) CA2829790C (enExample)
IL (3) IL222019A (enExample)
MX (1) MX355038B (enExample)
NZ (3) NZ718622A (enExample)
RU (2) RU2639876C2 (enExample)
SG (2) SG10201502484SA (enExample)
WO (1) WO2011126903A2 (enExample)
ZA (2) ZA201507923B (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
SG10201502484SA (en) * 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
ES2565193T3 (es) 2010-07-15 2016-04-01 Sumitomo Dainippon Pharma Co., Ltd. Compuesto de pirazol
CN103619171B (zh) 2010-11-03 2015-11-25 陶氏益农公司 杀虫组合物和与其相关的方法
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102898386B (zh) 2011-07-27 2015-07-29 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
CN104010505B (zh) 2011-10-26 2017-03-15 陶氏益农公司 杀虫组合物和与其相关的方法
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
CN104125957B (zh) 2011-12-21 2016-05-25 拜耳知识产权有限责任公司 取代的苄基吡唑
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2870090A1 (en) 2012-04-27 2013-10-31 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014047111A1 (en) * 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
US8921401B2 (en) 2013-02-07 2014-12-30 Musc Foundation For Research Development Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
DK2968297T3 (en) * 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
WO2014149139A2 (en) * 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014202590A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9745285B2 (en) 2013-06-21 2017-08-29 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
KR20160072155A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
WO2015058024A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004941A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
BR112016007518A2 (pt) 2013-10-17 2017-08-01 Dow Agrosciences Llc processos para a preparação de compostos pesticidas
CN105636441B (zh) 2013-10-17 2018-06-15 美国陶氏益农公司 制备杀虫化合物的方法
US9085564B2 (en) 2013-10-17 2015-07-21 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
US9029554B1 (en) 2013-10-17 2015-05-12 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
NZ719634A (en) 2013-10-22 2017-09-29 Dow Agrosciences Llc Pesticidal compositions and related methods
JP2016534086A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
US9801383B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105658062A (zh) 2013-10-22 2016-06-08 美国陶氏益农公司 协同杀虫组合物和相关方法
TW201519774A (zh) 2013-10-22 2015-06-01 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（六）
AR098102A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
EP3060045A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
CN105792651A (zh) 2013-10-22 2016-07-20 美国陶氏益农公司 杀虫组合物和与其相关的方法
US9149040B2 (en) 2013-10-22 2015-10-06 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9788546B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
WO2015061175A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2016119359A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и связанные с ними способы
US9144241B2 (en) 2013-10-22 2015-09-29 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
EP3060043B1 (en) 2013-10-22 2025-11-26 Corteva Agriscience LLC Pesticidal compositions and related methods
AU2014340437B2 (en) 2013-10-22 2017-09-07 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105828608A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 杀虫组合物和与其相关的方法
KR20160077113A (ko) 2013-10-22 2016-07-01 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 관련 방법
CN105764893A (zh) 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
JP6447496B2 (ja) 2014-01-29 2019-01-09 東レ株式会社 多発性硬化症の治療剤又は予防剤
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CA2954631A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
CA2954747A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Lcc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9029555B1 (en) 2014-07-31 2015-05-12 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112017002735A2 (pt) 2014-08-19 2017-12-19 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
BR112017003918B1 (pt) * 2014-08-29 2022-05-03 Fmc Corporation Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação
KR20170058388A (ko) 2014-09-12 2017-05-26 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP2017528486A (ja) * 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
JP6588027B2 (ja) 2014-10-24 2019-10-09 武田薬品工業株式会社 複素環化合物
WO2016108249A1 (en) * 2014-12-29 2016-07-07 Council Of Scientific & Industrial Research 1,2,4-triazole, 1,3,4-oxadiazole, and 1,3,4-thiadiazole derivatives and their antimycobacterial activity
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
ES2931460T3 (es) * 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
CN105218436B (zh) * 2015-10-21 2019-02-05 济南诚汇双达化工有限公司 一种制备4-氯-2-吡啶甲酸甲酯的方法
WO2017123518A1 (en) * 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
CN109311824B (zh) * 2016-03-10 2026-06-19 北京生命科学研究所 激酶抑制剂
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
CA3025810A1 (en) * 2016-05-23 2017-11-30 Manish P. PONDA Aminoacylindazole immunomodulators for treatment of autoimmune diseases
EP3498794B1 (en) 2016-08-08 2021-02-10 Asahi Kasei Kabushiki Kaisha Coating composition dispersion, aqueous dispersion of composite-particles, and method for producing aqueous dispersion of composite-particles
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3600328A4 (en) 2017-03-24 2021-01-06 3100 Central Expressway LLC MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2021012250A (es) 2019-04-11 2022-01-18 Angion Biomedica Corp Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
CN112062692A (zh) * 2019-06-11 2020-12-11 太仓市茜泾化工有限公司 一种乙氧甲叉氰基乙酸乙酯的制备方法
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
TW202320786A (zh) 2021-08-10 2023-06-01 美商蕾瑞拉股份有限公司 用於毛髮治療的組合物、調配物及方法
WO2023064458A1 (en) * 2021-10-13 2023-04-20 Yale University Selective jak2 inhibitors and methods of use
US12251459B2 (en) * 2022-10-12 2025-03-18 Oddity Labs, Llc Compositions, formulations, and methods for hair treatment
CN116535356B (zh) * 2023-03-06 2026-03-17 中国药科大学 3-氨基-5-苯基-吡唑类衍生物微管蛋白抑制剂及其制备和医药用途
CN116730980A (zh) * 2023-06-26 2023-09-12 合肥工业大学智能制造技术研究院 一种化合物及其立体异构体、或其药学上可接受盐与用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250761A (en) * 1962-01-23 1966-05-10 Ciba Geigy Corp New sulfonamides
US4008249A (en) * 1974-03-01 1977-02-15 Basf Aktiengesellschaft Substituted pyrazoles
US5739083A (en) * 1995-10-13 1998-04-14 Otsuka Kagaku Kabushiki Kaisha Pyrazole derivatives and insecticidal compositions containing the derivative as active component
WO2004000785A2 (en) * 2002-06-19 2003-12-31 Smithkline Beecham Corporation Phenyloxyalkanonic acid derivatives as hppar activators
RU2221808C2 (ru) * 1998-12-29 2004-01-20 Эл Джи Лайф Саенсиз Лтд. Ингибиторы тромбина
WO2004089911A1 (en) * 2003-04-10 2004-10-21 Merck Sharp & Dohme Limited Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer’s disease
US20080275070A1 (en) * 2005-05-26 2008-11-06 Shenyang Research Institute Of Chemical Industry Aryl Ether Compounds and Their Preparation and Use Thereof
US20100210696A1 (en) * 2007-09-28 2010-08-19 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793955A (fr) * 1972-01-15 1973-07-12 Merck Patent Gmbh Arylpiperazines et leur procede de preparation
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
IL82542A0 (en) 1986-05-23 1987-11-30 Smithkline Beckman Corp Triazole derivatives,their preparation and pharmaceutical compositions containing them
JPH089541B2 (ja) 1988-03-07 1996-01-31 三井東圧化学株式会社 ピラゾール類を主成分とする脳浮腫抑制剤
JP2784925B2 (ja) 1988-09-07 1998-08-13 日本農薬株式会社 ３又は５−フェニルピラゾール類又はその塩及び除草剤
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
DE4309213A1 (de) * 1992-09-11 1994-09-29 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP3810097B2 (ja) 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−２−イルカルボニル複素環式化合物誘導体
CA2277954A1 (en) 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5733955A (en) 1995-02-10 1998-03-31 The Goodyear Tire & Rubber Company Asphalt cement modification
JP3663522B2 (ja) 1995-08-12 2005-06-22 日本農薬株式会社 植物生育調節用組成物及びその使用方法
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5792761A (en) * 1996-08-12 1998-08-11 Merck & Co., Inc. Thrombin inhibitors
DE19632773A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
GB9622370D0 (en) 1996-10-28 1997-01-08 Merck Sharp & Dohme Therapeutic agents
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
BR9808398A (pt) 1997-03-21 2000-05-16 Novartis Ag Derivados pirazol com atividade herbicida
WO2000009500A2 (en) * 1998-08-11 2000-02-24 Nihon Bayer Agrochem K.K. Nematicidal pyrazoles
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
WO2000071536A1 (en) 1999-05-20 2000-11-30 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
MXPA02001498A (es) * 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
KR100479137B1 (ko) 1999-12-02 2005-03-31 노파르티스 아게 살충제 및 항기생충제로서의 아미노헤테로시클릴아미드
US6188045B1 (en) 2000-04-03 2001-02-13 Alto-Shaam, Inc. Combination oven with three-stage water atomizer
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
SI21097A (sl) 2001-12-04 2003-06-30 Univerza V Ljubljani Inhibitorji trombina
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
EP1509505A2 (en) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
JP2003313103A (ja) 2002-02-20 2003-11-06 Sankyo Agro Kk ４−アシルアミノピラゾール誘導体を有効成分として含有する農薬
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
AU2003274025A1 (en) 2002-10-17 2004-05-04 Syngenta Participations Ag Pyridine derivatives useful as herbicides
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
AU2003292218A1 (en) 2002-12-23 2004-07-14 Sanofi-Aventis Deutschland Gmbh PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
WO2004058722A1 (en) 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
US20040147561A1 (en) 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
JP2004231528A (ja) 2003-01-28 2004-08-19 Sankyo Agro Kk アミド誘導体
EP1617840A4 (en) 2003-05-01 2008-08-20 Bristol Myers Squibb Co PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS
ATE410161T1 (de) 2003-05-02 2008-10-15 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479679A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Triazole-derivatives as factor Xa inhibitors
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US20060281803A1 (en) 2003-09-23 2006-12-14 Lindsley Craig W Pyrazole modulators of metabotropic glutamate receptors
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN101137414A (zh) * 2004-12-31 2008-03-05 欧兰拓制药股份有限公司 多环双酰胺mmp抑制剂
US8084451B2 (en) 2005-01-10 2011-12-27 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
WO2006109846A1 (ja) * 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
JP2009518442A (ja) 2005-12-05 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物
US20090118336A1 (en) 2006-05-03 2009-05-07 Laurent David Pyrazole derivatives and their use as pi3k inhibitors
EP2035005A4 (en) * 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
DE102006032824A1 (de) 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
JP2009543842A (ja) 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008023235A1 (en) 2006-08-25 2008-02-28 Pfizer Products Inc. Pyrazole derivatives as anti-platelet and anti-thrombotic agents
EP2096111A1 (en) 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US7795249B2 (en) 2006-12-22 2010-09-14 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008105383A1 (ja) 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
AU2008284746A1 (en) 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. Aminopyrazole amide derivative
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8658685B2 (en) 2008-01-31 2014-02-25 Activesite Pharmaceuticals, Inc. Methods for treatment of kallikrein-related disorders
EP2254572B1 (en) 2008-02-07 2013-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
CA2724413C (en) 2008-05-15 2016-10-18 Duke University Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
JP5504259B2 (ja) 2008-05-19 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション 第ｉｘａ因子阻害剤としての複素環式化合物
CN102149379A (zh) 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US20110190365A1 (en) 2008-08-14 2011-08-04 Bayer Crop Science Ag Insecticidal 4-phenyl-1H-pyrazoles
CA2734804A1 (en) 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
JP2012500245A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経皮的インターベンション心臓カテーテル法のためのダビガトラン
JP2012500244A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍療法におけるダビガトラン
PL2427436T3 (pl) * 2009-05-07 2013-06-28 Gruenenthal Gmbh Podstawione aromatyczne pochodne karboksamidu i mocznika jako ligandy receptora waniloidowego
SG10201502484SA (en) * 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN101851207B (zh) 2010-06-11 2012-01-25 扬州康伊尔医药科技有限公司 抗病毒化合物中间体1-酰基-吡唑-3-羧酸及其制备方法
CN103619171B (zh) 2010-11-03 2015-11-25 陶氏益农公司 杀虫组合物和与其相关的方法
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
CA2844729A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Serine/threonine pak1 inhibitors
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
DK2968297T3 (en) * 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250761A (en) * 1962-01-23 1966-05-10 Ciba Geigy Corp New sulfonamides
US4008249A (en) * 1974-03-01 1977-02-15 Basf Aktiengesellschaft Substituted pyrazoles
US5739083A (en) * 1995-10-13 1998-04-14 Otsuka Kagaku Kabushiki Kaisha Pyrazole derivatives and insecticidal compositions containing the derivative as active component
RU2221808C2 (ru) * 1998-12-29 2004-01-20 Эл Джи Лайф Саенсиз Лтд. Ингибиторы тромбина
WO2004000785A2 (en) * 2002-06-19 2003-12-31 Smithkline Beecham Corporation Phenyloxyalkanonic acid derivatives as hppar activators
WO2004089911A1 (en) * 2003-04-10 2004-10-21 Merck Sharp & Dohme Limited Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer’s disease
US20080275070A1 (en) * 2005-05-26 2008-11-06 Shenyang Research Institute Of Chemical Industry Aryl Ether Compounds and Their Preparation and Use Thereof
US20100210696A1 (en) * 2007-09-28 2010-08-19 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound

Also Published As

Publication number Publication date
US9533967B2 (en) 2017-01-03
JP6650983B2 (ja) 2020-02-19
IL222019A (en) 2016-03-31
IL243989B (en) 2020-04-30
SG10201502484SA (en) 2015-05-28
CN110269856A (zh) 2019-09-24
US20160122333A1 (en) 2016-05-05
NZ700332A (en) 2017-06-30
JP6411390B2 (ja) 2018-10-24
KR102113960B1 (ko) 2020-05-21
IL243990A0 (en) 2016-04-21
US10653674B2 (en) 2020-05-19
WO2011126903A3 (en) 2012-02-23
ZA201507923B (en) 2020-05-27
US20160256440A1 (en) 2016-09-08
CN102918034B (zh) 2015-06-03
SG184243A1 (en) 2012-10-30
AU2011238616A1 (en) 2012-11-15
AU2016206247B2 (en) 2018-10-04
RU2017144535A (ru) 2019-02-18
JP2019011352A (ja) 2019-01-24
MX2012011380A (es) 2013-04-03
US20130040950A1 (en) 2013-02-14
EP2560966A4 (en) 2013-09-25
KR20130053404A (ko) 2013-05-23
CA2829790A1 (en) 2011-10-13
CN102918034A (zh) 2013-02-06
CA2829790C (en) 2018-06-05
JP2013523763A (ja) 2013-06-17
JP2016155812A (ja) 2016-09-01
NZ718622A (en) 2018-03-23
ZA201707157B (en) 2019-01-30
US20180214418A1 (en) 2018-08-02
EP2560966B1 (en) 2021-01-06
KR20190026055A (ko) 2019-03-12
BR112012024678A2 (pt) 2016-06-07
EP2560966A2 (en) 2013-02-27
IL243989A0 (en) 2016-04-21
CN104940200B (zh) 2019-06-28
AU2011238616B2 (en) 2016-08-04
CN104940200A (zh) 2015-09-30
JP6155187B2 (ja) 2017-06-28
NZ603156A (en) 2014-10-31
WO2011126903A2 (en) 2011-10-13
AU2019200013A1 (en) 2019-01-24
IL243990B (en) 2020-02-27
RU2012146194A (ru) 2014-05-10
AU2016206247A1 (en) 2016-08-04
US20160136177A1 (en) 2016-05-19
MX355038B (es) 2018-03-28
KR20180028536A (ko) 2018-03-16
US9963440B2 (en) 2018-05-08
KR101955691B1 (ko) 2019-03-07

Similar Documents

Publication Publication Date Title
AU2016206247B2 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
AU2018200736B2 (en) Multisubstituted aromatic compounds as serine protease inhibitors
US20170326125A1 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
EP2970141A2 (en) Halogenopyrazoles as inhibitors of thrombin
HK1214142B (en) Multisubstituted aromatic compounds as serine protease inhibitors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210331